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Abstract
Background: The regional lymph node involvement is a major prognostic factor in patients with non-small cell
lung cancer (NSCLC) undergoing surgical resection. Disease relapse is common, suggesting that early disseminated
disease is already present in the regional lymph nodes at the time of surgery, and that the current nodal staging
classification might be suboptimal. Early detection of disseminated tumor cells (DTCs) in lymph nodes could
potentially enable identification of subcategories of patients with high risk of disease relapse.
Method: Lymph node samples were collected from 128 NSCLC patients at the time of surgery and the presence of
DTCs determined by immunomagnetic selection (IMS) using the MOC31 antibody recognizing EpCAM. Results
obtained with IMS were compared to the pathological staging obtained by histopathology. Associations between
the presence of DTCs and clinicopathological variables and patient outcome were investigated.
Results: DTCs were detected in 40 % of the lymph node samples by IMS. Their presence was significantly
associated with pN status as assessed by histopathology, and samples from 83 % of the patients with lymph
node metastases (pN1-2) had detectable DTCs. In the group of patients who were negative for lymph node
metastases by standard histopathology (pN0) DTCs were detected in 32 %. The presence of DTCs was not
associated with any other clinicopathological variables. Patients with IMS-positive samples showed decreased
relapse free survival compared to patients with IMS-negative samples, but the difference was not statistically
significant. The pN status was significantly associated with both relapse free and overall survival, but the
presence of DTCs had no prognostic impact in the subcategory of patients with pN0 status.
Conclusion: Our findings do not support further development of lymph node DTC detection for clinical use
in early stage NSCLC.
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Background
Curatively intended surgical resection is the standard ther-
apy for operable patients with early-stage non-small cell
lung cancer (NSCLC), and the prognosis of these patients
is closely related to disease stage [1]. The regional lymph
node involvement is a major prognostic factor, and for
complete surgical resection of NSCLC a systematic nodal
dissection is recommended [2]. This allows pathological
staging of the disease according to standardized defini-
tions, and thereby decision of further treatment strategies.
The fact that approximately half of the patients undergo-
ing surgery experience disease relapse, suggests that dis-
seminated tumor cells (DTCs) may be present already at
the time of surgery [3]. In routine clinical practice, patho-
logical evaluation of resected lymph nodes is done by
standard histopathology, a method by which DTCs cannot
be identified. The high recurrence rate after surgical resec-
tion of NSCLC indicates that current staging classifica-
tions are not able to accurately predict patient outcome
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and that the nodal staging might be suboptimal. Detection
of DTCs to regional lymph nodes at the time of surgery
could possibly facilitate identification of subcategories of
patients with high risk of disease relapse, and thereby
stratification of patient groups for adjuvant therapy.
Occult metastatic spread to the lymph nodes or distant
sites has been the focus of research over many years, and
has been reported under different terminology. The Union
for International Cancer Control (UICC) has defined
micrometastasis as clusters of tumor cells measuring be-
tween 0.2 and 2 mm in diameter, and isolated tumor cells
as single tumor cells or small clusters of cells smaller than
0.2 mm [4]. Tumor cells that have spread to lymph nodes
or bone marrow are often referred to as DTCs, whereas cir-
culating tumor cells (CTCs) are used for single cells in
blood [5]. A number of previous studies have addressed the
prognostic value of detecting micrometastasis and DTCs in
lymph nodes of NSCLC patients [6–23], but due to consid-
erable differences in terminology, methodology and results,
no conclusion can be drawn based on the existing litera-
ture. The methods used for detection have traditionally
been immunohistochemistry (IHC) with antibodies target-
ing epithelial-specific proteins like cytokeratins [6–18], and
molecular methods using RT-PCR for detection of tumor-
or epithelial cell specific mRNA transcripts [3, 19–25]. Our
group has previously published a study where we investi-
gated the presence of DTCs in bone marrow aspirates from
patients undergoing lung cancer surgery by the use of
immunomagnetic selection (IMS) [26]. In the present study
we have used IMS to investigate the presence of DTCs in
lymph node tissue prospectively collected from patients
with early stage NSCLC undergoing curatively intended
surgery. In the IMS method small magnetic particles coated
with the antibody MOC31 which recognizes the epithelial
marker EpCAM, are used to isolate tumor cells from the
lymph nodes, allowing fast screening of as much as 2 ×
107 cells. The objective of our study was to determine
the incidence of lymph node DTCs, and to compare
results obtained with IMS to the pathological staging
obtained by histopathology. Additionally, we wanted to
investigate the associations between the presence of
DTCs and clinical and histopathological variables, as
well as to patient outcome.
Methods
Patients
Between November 2011 and September 2013 we in-
cluded 183 patients with assumed or verified NSCLC
who underwent curatively intended surgical resection at
Rikshospitalet, Oslo University Hospital. The project was
accepted by the institutional review board and Regional
Ethics Committee (S-06402b), the patients received oral
and written information and signed a consent form before
entering the project. At the time of surgery all patients
underwent radical resection of the primary tumor and dis-
section of the hilar and mediastinal lymph nodes. The ex-
cised lymph nodes were first divided into two parts, leaving
half the node for routine pathological review and one half
for research projects. One node from one lymph node sta-
tion per patient was made available for IMS analysis. Fifty-
five patients were excluded from the study for the following
reasons: histology other than NSCLC (13), inadequate ma-
terial for analysis (41) and withdrawn consent (1). The total
study population thus included 128 patients with histologi-
cally verified primary NSCLC. The resected tumor tissue
and lymph nodes were processed for routine histopatho-
logical assessment, and the histological subtypes were clas-
sified according to WHO criteria [27]. Tumors were staged
according to the Union for International Cancer Control
(UICC), TNM 7, and histopathological parameters were
retrieved from the pathology reports. After surgery, the pa-
tients were followed by clinical evaluation and radiological
examination in their corresponding local hospitals accord-
ing to national guidelines. We collected the follow-up infor-
mation from the patients’ local hospitals. Survival data were
obtained from the National Registry of Norway and
updated on January 30th, 2015.
Immunomagnetic selection
The immunomagnetic selection was performed as de-
scribed previously [28, 29], and a schematic drawing of
the method is shown in Fig. 1. The lymph node tissue
Fig. 1 Schematic overview of the IMS technique. Fresh lymph node samples were disintegrated in sterile PBS, followed by filtration, centrifugation, dilution
and aliquotation of the cell suspensions. The cells were then mixed with either MOC31 coated magnetic beads (anti-EpCAM) or beads without antibodies
for control. The samples were incubated under continuous rotation at 4 °C for 30 min, and placed on a magnet to separate bead-bound and unbound
cells. The supernatant containing the unbound cells was removed, and fractions of the cell suspension were examined in the light microscope
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was placed in a petri dish containing 10 ml phosphate
buffered saline (PBS) containing 1 % human serum albu-
min (HSA) for disaggregation using scalpels. The disag-
gregated tissue was then filtered through a 70 μm cell
strainer (BD Biosciences, Franklin Lakes, NJ, USA) into
a 50 ml tube, and the cell strainer was washed with PBS/
1 % HSA. The filtered cell suspension was concentrated
by centrifugation at 500 g for ten minutes. The cells
were then resuspended in 1 ml PBS/1 % HSA, and trans-
ferred to round bottom tubes for incubation with
antibody-coated beads. Dynabeads M450 sheep anti-
mouse (SAM) IgG1 (Dynal, Oslo, Norway) were coated
with MOC31 antibody (batch # 80.000, IQ products,
Groningen, The Netherlands). Uncoated beads for con-
trol experiments were prepared in the same manner,
without adding the MOC31 antibody. Magnetic immu-
nobeads with or without the primary antibody were
added to tubes containing the cell suspension in a final
volume of 1 ml with a bead:cell ratio of 1:2. The samples
were then incubated on a rotating mixer for 30 min at
4 °C. After incubation the samples were diluted in PBS/
1 % HSA and exposed to a strong magnet for 3 min to
separate bound and unbound cells. The supernatant
containing the unbound cells was decanted off with the
tubes still in the magnet holder, and the positive fraction
was resuspended in PBS/1 % HSA. Fractions of 20 μl
from the cell suspension were then directly examined in
the light microscope to identify and count the number
of cells with membrane-bound beads. The cells were
also evaluated with respect to size, morphology and
three-dimensional shape. Cells were considered EpCAM
+ if they had five or more immunomagnetic beads at-
tached to the surface, and had diameters exceeding the
width of two beads.
Statistical analysis
Associations between the presence of lymph node DTCs
and clinicopathological variables were tested using two-
tailed Fisher’s exact test or linear by linear association
chi-square test. For analyses of associations between the
number of DTCs detected by IMS and clinicopathologi-
cal variables, two sample t-test or one-way ANOVA test,
as appropriate, was used. Survival curves were estimated
according to the Kaplan-Meier method, and differences
between the curves were compared using the log rank
test. Survival was measured from date of surgery until
date of diagnosis of recurrence or metastasis for relapse
free survival, and from date of surgery until death date
for overall survival. Cox proportional hazards regression
was used to estimate hazard ratios and 95 % confidence
intervals (CI). SPSS statistical software version 18.0
(SPSS Inc., Chicago, IL, USA) was used for all the statis-
tical analyses. P-values < 0.05 were considered statisti-
cally significant.
Results
Characteristics of the patient cohort
The clinical and histopathological baseline data of the
study cohort are summarized in Table 1. The study co-
hort consisted of 44 % female and 56 % male patients,
with a mean age of 66 years (range 42 – 85). Adenocar-
cinoma was the most frequent histological subtype
(57 % of patients), followed by squamous cell carcin-
oma (39 %) and large cell carcinoma (4 %). Sixty
percent of patients were in pTNM stage I, 27 % of
patients were in pTNM II, 10 % in pTNM III and 4
patients (3 %) were in stage IV. As assessed by standard
histopathology the majority of patients (80 %) were
negative for lymph node metastases and staged as pN0.
Among the 26 patients in whom lymph node metasta-
ses were detected, 14 % were categorized as pN1 and
6 % as pN2.
Table 1 Demographics of patient cohort (N = 128)
Parameter Patients
N %
Sex Male 71 56
Female 57 44
Age at surgery <65 years 52 41
> 65 years 76 59
Histology Adenocarcinoma 73 57
Squamous cell carcinoma 50 39
Large cell carcinoma 5 4








pN pN0 102 80
pN1 18 14
pN2 8 6
Tumour size (cm) ≤ 2.0 cm 32 25
2.1–3.0 cm 27 21
3.1–5.0 cm 46 36
5.1–7.0 cm 10 8
>7.0 cm 13 10
Tobacco use Current smoker 77 60
Former smoker 46 36
Never smoker 6 5
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Detection of DTCs by IMS
In nine cases the sampled lymph node station was not
registered, resulting in a total of 119 cases for the meth-
odological analyses. Based on our experience with IMS
and our previous publication [26], the cutoff for a posi-
tive sample was 10 cells, meaning that a sample with 11
or more EpCAM+ cells was classified as IMS-positive. In
47 of 119 samples (40 %) > 10 EpCAM+ cells were
detected, and the median number of cells in the IMS-
positive samples was 61 (range 14 – 200). Between 11
and 50 EpCAM+ cells were detected in 45 % of positive
samples, 51 – 100 EpCAM+ cells were detected in 28 %
and ≥ 100 cells were detected in 28 % of the positive
samples. Associations between the presence of EpCAM+
cells and the clinicopathological characteristics of the
patients are summarized in Table 2. The presence of
EpCAM+ cells was significantly associated with pN
status (p < 0.001, Table 2). Lymph node samples from 9/
11 (82 %) pN1 patients and 5/6 (83 %) pN2 patients,
respectively, were IMS-positive. Three of 17 patients
(18 %) in whom lymph node metastases were detected
by histopathology (pN1-2) were categorized as IMS-
negative. In the subcategory of patients who were nega-
tive for lymph node metastases by histopathology (pN0),
32 % (33/102) were IMS-positive (Table 2). The exact
number of EpCAM+ cells in each sample was also sig-
nificantly associated with pN status (p < 0.001, one-way
ANOVA test). In fact, 4/6 (67 %) of patients with pN2
status had more than 100 EpCAM+ cells in their
samples, compared to only 8/102 (8 %) of the patients
with pN0 status. Analyzing the relationship between
the IMS results and the other clinicopathological
parameters revealed no association with gender, age,
histology, pTNM, pT status, tumor size or tobacco
smoking habits (Table 2).
Patient outcome and associations with clinicopathological
parameters
For the follow-up and survival analyses the four patients
with stage IV disease were excluded, resulting in a co-
hort of 124 patients. Median follow-up time for patients
still alive who had not developed metastasis or local re-
currence was 26 months (range 16 –38). Twenty-five of
124 patients (20 %) developed disease relapse, while 24
patients (19 %) died during the follow-up period. Associ-
ations between clinicopathological variables and patient
outcome are shown in Table 3. Univariate analyses re-
vealed that pTNM stage and pN status were significantly
associated with disease relapse (p < 0.001 and p = 0.001,
respectively) and with overall survival (p = 0.002 and
0.005, respectively). There was a significant association
between patient outcome and gender, with a 2-year re-
lapse free survival rate of 87 % for females, compared to
70 % for males (p = 0.03). A relationship between histo-
logical subtype and patient outcome was also detected,
however this result was caused by the fact that three out
of four patients with large cell carcinoma relapsed, and
should be interpreted with caution due to the small
number of patients in the subcategory.
Associations between DTCs and patient outcome
There was a small, non-significant difference in relapse
free survival between patients with IMS-negative and
IMS-positive lymph node samples (p = 0.17, Fig. 2b and
Table 3). Two-year relapse free survival for IMS-negative
patients was 82 %, compared to 71 % for IMS-positive
patients. There was no association to overall survival
(p = 0.77, Table 3). Twenty-six percent (13/50) of
patients with IMS-positive samples developed disease
relapse during the follow-up period, compared to 16 %
(12/74) of patients with IMS-negative samples. The
exact number of EpCAM+ cells detected by IMS was
not associated with disease relapse (p = 0.57, Cox uni-
variate analysis). We performed subcategory analyses
Table 2 Relationship between the presence of DTCs as
detected by IMS and clinicopathological variables (N = 119 a)
Parameter Nb %b p-value
Gender male 28 44
female 19 35 0.36
Age at surgery < 65 years 22 46
> 65 years 25 35 0.26
Histology ADC 26 38
SCC 19 40
LCC 2 50 0.89
pTNM I 26 34
II 13 45
III 7 78
IV 1 25 0.12
pT pT1 20 51
pT2 19 33
pT3 8 38
pT4 0 0 0.15
pN pN 0 33 32
pN I 9 82
pN II 5 83 < 0.001
Tumor size (cm) ≤ 3.0 cm 26 47
≥ 3.1 cm 21 33 0.13
Tobacco Never smoker 2 33
Former smoker 20 47
Current smoker 25 36 0.54
aNine patients excluded from analysis due to uncertain lymph node station
bThe number and percentage of positive samples are shown
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Table 3 Univariate analysis of associations between clinicopathological variables and patient outcome (N = 124a)
Relapse free survival Overall survival
Parameter p Hazard ratio (95 % CI) p Hazard ratio (95 % CI)
Gender 0.03 0.9
Female
Male 2.7 (1.1–6.8) 1.1 (0.5–2.4)
Age 0.06 0.3
> 65 years
< 65 years 2.8 (0.9–8.6) 1.5 (0.7–3.3)
Histology 0.01 0.04
Adenocarcinoma
Squamous cell carcinoma 0.7 (0.3–1.8) 0.5 (0.2–1.2)
Large cell carcinoma 9.6 (2.7–34.0) 4.7 (1.1–20.1)
pTNM < 0.001 0.002
I
II 1.7 (0.6–4.5) 2.2 (0.8–5.7)
III 8.8 (3.4–22.4) 7.1 (2.6–19.2)
pT 0.07 0.02
pT1 1.7 (0.6–5.6)





pN1 3.6 (1.4–9.1) 3.5 (1.4–8.9)
pN2 8.2 (2.9–23.0) 5.1 (1.7–15.8)
Tumor size 0.18 0.73
≤ 3.0 cm
≥ 3.1 cm 1.7 (0.8–3.9) 1.2 (0.5–2.6)
DTCs detected by IMS 0.18 0.77
IMS negative
IMS positive 1.7 (0.8–3.8) 1.1 (0.5–2.5)
aFour patients were excluded from survival analyses due to stage IV disease
Fig. 2 Kaplan-Meier survival plots depicting relapse-free survival based on pathological lymph node status (a), and based on the presence of DTCs
as detected by IMS in the overall patient cohort (b) and in the pN0 patient cohort (c)
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including only patients who were classified as pN0 by
histopathology, but found no difference in relapse free
survival (p = 0.92, Fig. 2c) or overall survival (p = 0.39,
data not shown) between IMS-negative and IMS-
positive patients. Similar to the whole patient cohort,
the exact number of EpCAM+ cells was not related to
disease relapse in this subcategory (p = 0.57, Cox
univariate analysis). Finally, dividing patients into
subcategories according to the number of EpCAM+
cells in the sample did not reveal any associations with
outcome.
Discussion
In the present study we have examined the presence and
prognostic implication of DTCs in prospectively
collected lymph node samples from early stage NSCLC
patients undergoing surgical resection. By using the
technique IMS with the EpCAM-targeting antibody
MOC31, we found a strong association between pN sta-
tus as assessed by standard histopathology and detection
of EpCAM+ cells. The pN status, but not the IMS result,
was significantly associated with patient outcome.
Among the patients staged as pN0 by histopathology,
32 % were categorized as IMS-positive, but IMS was not
able to predict prognosis in this patient subcategory.
Taken together, we conclude that detection of lymph
node DTCs by IMS does not improve nodal staging
in NSCLC patients, and cannot be used for identifica-
tion of patients with high risk of relapse after surgical
resection.
A number of publications have investigated the inci-
dence of micrometastatic disease or DTCs in lymph
nodes from patients with NSCLC, the majority using
IHC or RT-PCR, with conflicting results. Several
groups have shown an association between the pres-
ence of micrometastasis or DTCs and poor prognosis
[7, 8, 10, 11, 13, 14, 19–23] while other have con-
cluded like in our study, that their presence has no
impact on patient outcome [15–18]. Data from the
diverse publications are not easily comparable due to
differences in methodology as well as in size and
composition of patient cohorts. Also, various defini-
tions of the terms “micrometastases”, “occult tumor
cells” and “isolated tumor cells” have been used, and
many authors who demonstrated negative prognostic
value did not specify whether they investigated iso-
lated tumor cells or true micrometastasis [6, 14, 30].
In 2010, Herpel et al. [8] showed that nodal micro-
metastasis specifically defined as small tumor deposits
had prognostic significance, however two other stud-
ies investigating isolated tumor cells in regional
lymph nodes concluded that this did not affect sur-
vival in resected NSCLC patients [16, 17]. One might
hypothesize that NSCLC patients with detectable
single DTCs have similar prognosis to patients with
node negative disease, while patients with microme-
tastasis may have higher risk of relapse. Interestingly,
similar results have been found in breast cancer [31].
In a paper from 2008, Marchevsky et al. investigated
both isolated tumor cells and micrometastases in
lymph nodes from 266 stage I NSCLC patients, and
concluded that the presence of neither of these were
significantly associated with survival. The authors also
performed a meta-analysis including their own data
and 13 other studies, and concluded on no significant
association between micrometastasis and survival [18].
Thus, based on the current literature and our own re-
sults, detecting DTCs in regional lymph nodes does
not seem to provide a clinically useful method for identify-
ing subcategories of NSCLC patients with high risk of dis-
ease relapse. Previously we have also shown that detection
of DTCs in bone marrow by IMS has no prognostic im-
pact in early stage NSCLC patients [26].
The present study is, to our knowledge, the first to
use IMS as method for detection of DTCs in regional
lymph nodes from NSCLC patients. This technique
was developed in our lab, and has been used in
several published papers investigating DTCs in bone
marrow [26, 28, 32–35] and lymph nodes [36] in vari-
ous cancer types. Evaluation of morphology, size and
shape of the MOC31-bead-bound cells is challenging
when using IMS, and is dependent on the observer’s
skills and experience. In our study we found a high
number of MOC31-bead bound cells in the samples,
and the cut off value for an IMS-positive sample was
set at 10 cells based on experience and our previous
publication [26]. The high number of discovered cells
might indicate that some nonmalignant cells are also de-
tected with this method, and in fact lymph node reticulum
cells can express epithelial antigens [37, 38], and weak
binding of MOC31 to lymphocytes has been described
[39]. Interestingly, however, in a study using RT-PCR to
identify tumors cells in lymph nodes in a NSCLC
cohort comparable to ours, Nordgård et al. also
reported a high number of positive findings in histo-
pathologically node negative patients [40]. Another
important issue when using antibodies targeting
EpCAM is that the expression of this protein may
vary in tumor cells during disease progression [41],
and expression can be down-regulated as a conse-
quence of epithelial-to-mesenchymal transition (EMT)
[42]. This might perhaps explain why no EpCAM+
cells were discovered in 3 of 17 lymph node samples
from patients who had metastases detected by routine
histopathology. There are clearly several methodo-
logical issues associated with the use of IMS, leading
to considerable challenges for the further develop-
ment and application of this method.
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Our study is limited by the fact that we only had ac-
cess to one lymph node sample from one node station
per patient. Analyzing a number of nodes from various
stations from each patient would of course have been
preferable. Moreover, a larger patient cohort and longer
follow-up period would increase the reliability of our re-
sults. However, we were able to detect EpCAM+ cells in
the vast majority of samples from lymph nodes in which
metastases had been shown on histopathology, and there
was a strong association between results from the IMS
method and nodal staging by standard histopathology.
Conclusion
We conclude that detecting EpCAM+ cell in regional
lymph nodes by IMS does not predict the prognosis of
resected NSCLC patients, as the presence of such cells
in patients who were lymph node negative showed no
association with reduced survival. Our findings do not
support further development of assays for detection of
DTCs in lymph nodes for clinical use in NSCLC.
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